MODELING OF PHARMACEUTICAL PROPAGATION AND PARAMETER GENERATION FOR INJECTION PROTOCOLS

• US 20130211247A1
• Filed: 06/24/2011
• Published: 08/15/2013
• Est. Priority Date: 06/24/2010
• Status: Active Grant

• Current Assignee: Bayer Healthcare LLC (Bayer AG)
• Original Assignee: Medrad Incorporated (Bayer AG)
• Inventors: Kalafut, John F.
• Granted Patent: US 9,959,389 B2
• Time in Patent Office: Days
• US Class Current: 600/432
• CPC Class Codes: A61B 6/507 for determination of haemodynamic parameters, e.g. perfusion CT
• CPC Class Codes: G16H 50/50 for simulation or modelling of medical disorders

Abstract

A system includes a parameter generation system to determine at least one parameter for an injection procedure (for example, a parameter of an injection protocol or an imaging system parameter), the parameter generator system includes a physiologically based pharmacokinetic model to model propagation of a contrast medium injected into a patient including at least one of a non-linear saturation term in a peripheral venous compartment, at least one configurable transport delay term through at least one compartment, or an adaptation to model volumetric flow rate of blood and an effect thereof on the propagation of contrast medium after injection of contrast medium ceases. The physiologically based pharmacokinetic model can, for example, be discretizable.

Claims

1. A method of modeling propagation of contrast medium including a contrast enhancing agent injected into a patient using a physiologically based pharmacokinetic model, comprising:

incorporating into the physiologically based pharmacokinetic model at least one of a non-linear saturation term in a peripheral venous compartment, or at least one configurable transport delay term through at least one compartment.

2. The method of claim 1 wherein the physiologically based pharmacokinetic model is adapted to estimate a time enhancement curve for a region of interest of the patient.

3. The method of claim 1 wherein the at least one configurable transport delay is configurable at least in part on the basis of at least one patient specific variable.

4. The method of claim 1 wherein the physiologically based pharmacokinetic model is adapted to model propagation of contrast medium after injection of contrast medium has ceased.

5. The method of claim 4 wherein the physiologically based pharmacokinetic model models volumetric flow rate of blood and the effect thereof on propagation of contrast medium.

6. The method of claim 5 wherein the physiologically based pharmacokinetic model models an effect on propagation of contrast medium upon injection of a fluid containing no contrast enhancing agent after injection of contrast medium.

9. The method of claim 1 wherein at least one parameter for the physiologically based pharmacokinetic model is determined at least partially on the basis of data from multiple individuals.

10. The method of claim 1 wherein at least one parameter for the physiologically based pharmacokinetic model is determined at least partially on the basis of at least one patient specific variable.

11. The method of claim 1 wherein at least one parameter for the physiologically based pharmacokinetic model is determined at least in part from at least one time enhancement curve of the patient resulting from an injection of contrast medium.

14. The method of claim 1 wherein the physiologically based pharmacokinetic model is incorporated in a system comprising an injector system and an imaging system and is used in generating at least one parameters for an injection procedure.

16. The method of claim 2 further comprising using the physiologically based pharmacokinetic model to estimate a time enhancement curve for the patient and determining at least one parameter of an injection procedure at least in part on the estimated time enhancement curve.

7. (canceled)

8. (canceled)

12. (canceled)

13. (canceled)

15. (canceled)

17. (canceled)

18. A method of modeling propagation of contrast medium injected into a patient using a physiologically based pharmacokinetic model, comprising:

modeling volumetric flow rate of blood and the effect thereof on the propagation of contrast medium after injection of contrast medium ceases.

19. The method of claim 18 wherein the physiologically based pharmacokinetic model models an effect on propagation of contrast medium upon injection of a fluid containing no contrast enhancing agent after injection of contrast medium.

22. The method of claim 19 wherein the physiologically based pharmacokinetic model is adapted to estimate a time enhancement curve for a region of interest of the patient.

23. The method of claim 19 wherein the physiologically based pharmacokinetic model comprises at least one non-linear saturation term in a peripheral venous compartment or at least one configurable transport delay term through at least one compartment.

25. The method of claim 19 wherein at least one parameter for the physiologically based pharmacokinetic model is at least in part on the basis of data from multiple individuals.

26. The method of claim 19 wherein at least one parameter for the physiologically based pharmacokinetic model is determined at least partially on the basis of at least one patient specific variable.

27. The method of claim 19 wherein at least one parameter for the physiologically based pharmacokinetic model is determined at least in part on the basis of at least one time enhancement curve of the patient resulting from an injection of contrast medium.

32. The method of claim 22 further comprising using the physiologically based pharmacokinetic model to estimate a time enhancement curve for the patient and determining at least one parameter of an injection procedure at least in part on the estimated time enhancement curve.

33. The method of claim 32 further comprising using a time enhancement curve during a diagnostic injection of contrast medium to update the model and to alter at least on parameter of the injection procedure.

20. (canceled)

21. (canceled)

24. (canceled)

28. (canceled)

29. (canceled)

30. (canceled)

31. (canceled)

34. A system comprising a parameter generation system to determine at least one parameter for an injection procedure, the parameter generator system comprising a physiologically based pharmacokinetic model to model propagation of a contrast medium injected into a patient comprising at least one of a non-linear saturation term in a peripheral venous compartment, at least one configurable transport delay term through at least one compartment, or an adaptation to model volumetric flow rate of blood and an effect thereof on the propagation of contrast medium after injection of contrast medium ceases.

36. The system of claim 34 wherein at least one parameter for the physiologically based pharmacokinetic model is determined at least in part from at least one time enhancement curve of the patient.

39. The system of claim 34 further comprising a non-parametric model to model propagation of a contrast medium injected into a patient.

41. The system of claim 34 wherein the at least one parameter is determined using an optimization method on the basis of the physiologically based pharmacokinetic model.

43. The system of claim 39 wherein the at least one parameter is determined using an optimization method on the basis of at least one of the physiologically based pharmacokinetic model or the non parametric model.

35. (canceled)

37. (canceled)

38. (canceled)

40. (canceled)

42. (canceled)

44. (canceled)